solver.press

**GPU-accelerated agent-based molecular pathway simulations (cancer therapy design) will exhibit coalition-based equilibrium deviations (beyond Nash) when modeling drug-resistant subclonal interactions, where rare cell populations act as coordinated "deviator coalitions" to evade therapeutic pressure.**

BiologyAug 1, 2026Evaluation Score: 71%

Adversarial Debate Score

55% survival rate under critique

Expert panel critique

Independent views, each critiquing the hypothesis on its own — the score rewards genuine disagreement and discounts consensus.

Gemini: ** **Strengths:** The hypothesis is highly falsifiable, biologically plausible (leveraging phenotypic heterogeneity and subclonal interactions from the literature), and computationally feasible via GPU acceleration. **Weaknesses:** While the core hypothesis is conceptually sound, the owner's v...
Mistral: ** The hypothesis is **falsifiable, biologically plausible, and partially supported by prior work** (e.g., agent-based modeling of subclonal interactions, emergent resistance dynamics). However, **it lacks direct empirical validation** from the owner’s experiments (which focus on precision/optim...
ChatGPT: The hypothesis is potentially falsifiable if coalition membership, payoffs, and equilibrium-deviation criteria are explicitly defined, but the cited papers support only the modeling framework and tumor heterogeneity—not coordinated coalitional behavior beyond Nash. The validated experiments are u...
Claude: The hypothesis is conceptually interesting and partially grounded in the GPU-accelerated ABM literature cited, but it conflates computational game-theoretic constructs (coalition/Nash equilibria) with emergent biological subclonal dynamics without a mechanistic bridge or falsifiable experimental ...

Supporting Research Papers

Computational Result

📖 Literature-assessed (LLM)· literature_meta

An LLM's reading of the literature — not computational verification.

Coalition behavior in drug resistance remains uncertain and requires further investigation.

Method: literature_meta · Result: inconclusive · Confidence: 60%

Formal Verification

Z3 logical consistency:✅ Consistent

Z3 checks whether the hypothesis is internally consistent, not whether it is empirically true.

Experimental Validation Package

This discovery has a Claude-generated validation package with a full experimental design.

Precise Hypothesis

In GPU-accelerated agent-based models (ABMs) of tumor subclonal populations under therapeutic drug pressure, rare drug-resistant subclones will exhibit emergent "coalition-like" behaviors — statistically correlated, mutually reinforcing strategy shifts (e.g., synchronized phenotype switching, paracrine signaling coordination, or metabolic resource-sharing) — that produce population-level equilibria deviating from the Nash equilibrium predicted by an equivalent non-cooperative game-theoretic model of the same pathway network. Specifically: the empirical steady-state distribution of resistant vs. sensitive subclone fractions under fixed drug dosing will differ from the Nash-predicted distribution by an effect size ≥0.2 (Cohen's d) in ≥60% of parameter regimes tested, and this deviation will be reducible (partially explained, R²≥0.3) by a coalition-formation model (e.g., cooperative game / core-based solution concept) fit to the same simulation trajectories.

Disproof criteria:
  • If, across ≥80% of tested parameter regimes, the ABM steady state matches the Nash-equilibrium prediction within effect size <0.1 (Cohen's d), the hypothesis is disproven for that mechanism class.
  • If a coalition-based (cooperative game / core / Shapley-value) model fit to the same trajectories explains no more variance (ΔR² ≤ 0.05) than a null model with added noise terms, the "coalition" framing is disproven as explanatorily useful (deviation may still exist but isn't coalition-structured).
  • If deviations disappear when inter-agent communication/signaling channels are ablated (control condition) at a rate inconsistent with a coalition mechanism (i.e., deviation persists without any communication channel), the causal claim is disproven.
  • If results are only reproducible under one specific random seed / initialization and fail a pre-registered replication (n=30 seeds, Bonferroni-corrected), disproven as a numerical artifact.

Spine & Adversarial ReadReady for validation

This hypothesis tests whether spatial agent-based tumor simulations incorporating inter-subclonal signaling produce steady-state resistant/sensitive population distributions that deviate from classical Nash-equilibrium predictions in a manner statistically attributable to coalition-like cooperative dynamics among resistant subclones.

  • highEvolutionary game theory in oncology (Gatenby, Brown, Basanta, and others) has for over a decade modeled frequency-dependent, non-Nash, ecologically-structured resistance dynamics; 'coalition deviation from Nash' may just be a relabeling of well-established spatial evolutionary game effects (kin selection, spatial reciprocity) without genuine new content.
    Unresolved in this EVP due to unavailable literature search — CLOSEST_EXISTING_WORK is empty because no search results were retrievable, not because none exist. This is a critical gap: before funding, a proper search of the adaptive-therapy/evolutionary-game-oncology literature (e.g., Moffitt Cancer Center group, Kaznatcheev's work on cancer game theory) must be conducted to determine if 'coalition-based deviation' is already a named, modeled phenomenon under a different term (e.g., 'group selection' or 'public goods games in cancer').
  • highWhy is a cooperative-game/Shapley-value framework the correct formalization of 'coalition behavior' rather than simpler alternatives (spatial correlation statistics, mean-field approximations with higher-order moments, or standard evolutionary game theory with added interaction terms)? The methodology does not justify why the cooperative game-theoretic lens adds explanatory value over already-standard spatial/frequency-dependent game models.
    Partially addressed via the ablation design (shuffled-signal control) which does test causal structure, but the choice of Shapley value/core as THE coalition metric (vs. e.g., simpler mutual-information or Granger-causality-based coordination metrics) is not independently justified. Protocol should be revised to include a model-comparison step against at least one non-cooperative-game null (e.g., higher-order mean-field model) to show the cooperative-game framing specifically outperforms simpler explanations, not just a noise null.
  • mediumThe 'rare cell populations acting as coordinated deviator coalitions' framing anthropomorphizes what may be purely emergent, non-intentional local optimization (each cell responding only to local gradients) — labeling this 'coalition' behavior may overclaim strategic coordination that doesn't exist at the mechanistic level.
    Addressed by disproof criteria requiring the cooperative-game model to add explanatory power beyond noise, but the philosophical distinction between 'emergent local optimization' and 'coalition' is not resolved — the EVP should explicitly state that 'coalition' is used as a mathematical/game-theoretic descriptor of outcome structure, not a claim about cellular intentionality, to preempt this critique in review.

Experimental Protocol

Minimum viable test (MVT):

  1. Build a spatial ABM (2D lattice, ~5,000–50,000 agents) of a single canonical resistance pathway (e.g., EGFR/MAPK with a known bypass mechanism, or AR-pathway prostate cancer resistance) with 3 agent types: drug-sensitive, resistant, and intermediate/persister.
  2. Implement a paracrine signaling channel (diffusible factor) enabling local cooperative benefit (e.g., resistant cells secreting a factor that protects neighboring sensitive cells — a documented biological phenomenon).
  3. Run the ABM under fixed dosing to steady state (GPU-accelerated, e.g., via CUDA/JAX/Taichi) for 200 parameter combinations (dose × diffusion range × cooperation strength × initial resistant fraction).
  4. In parallel, formulate an equivalent non-cooperative evolutionary game (replicator dynamics / normal-form game) using the same fitness payoffs stripped of spatial/signaling coupling; compute its Nash equilibrium analytically or via best-response iteration.
  5. Compare ABM steady-state distributions to Nash predictions; fit a cooperative-game solution concept (Shapley value allocation, core stability test) to ABM trajectories.
  6. Run ablation controls: (a) zero signaling range, (b) randomized/shuffled signaling (breaks coordination but preserves magnitude), (c) increasing agent count 10×/100× to test finite-size effects.
Required datasets:
  • No patient data required for MVT (synthetic ABM only). For extended validation: publicly available subclonal evolution datasets (e.g., TRACERx lung cancer multi-region sequencing, PCAWG resistance mutation timelines) to calibrate agent fitness/mutation parameters.
  • Pathway topology from a curated source (Reactome, KEGG) for the chosen cancer pathway (e.g., EGFR-TKI resistance in NSCLC).
  • Reference resistance-mechanism literature (e.g., documented paracrine/exosome resistance-transfer papers) to justify coupling term parameterization — must be logged as assumptions, not fit-free.
  • Simulation framework: existing open-source spatial ABM engine (e.g., PhysiCell, CompuCell3D) or custom GPU kernel (JAX/Taichi) — required as software dependency, not dataset per se.
Success:
  • ≥60% of 200 parameter regimes show Cohen's d ≥0.2 deviation from Nash prediction (p<0.05, FDR-corrected).
  • Cooperative-game model achieves R²≥0.3 in explaining ABM deviation patterns, with ΔR² ≥0.15 over null noise model.
  • Ablation confirms causal dependency: zero-signaling-range condition reduces deviation effect size by ≥50% relative to full-signaling condition.
  • Results replicate across ≥2 independent ABM engines/implementations with consistent direction of effect (same sign, overlapping CIs).
Failure:
  • <30% of regimes show meaningful deviation, OR cooperative model R²<0.1, OR ablation shows no reduction in deviation when signaling is removed (implies deviation is a numerical/finite-size artifact, not coalition behavior).
  • Effect fails to replicate across seeds (CI crosses zero in >50% of bootstrap resamples).
  • Effect fails to replicate across independent ABM implementations (software-specific artifact suspected).

ROI Projection

Commercial:

Direct application to oncology drug-combination simulation platforms (e.g., in silico trial design tools used by pharma for resistance modeling). A validated coalition-detection module could be licensed as an add-on to existing ABM/digital-twin cancer simulation platforms. Broader value: the coalition-game analytical framework generalizes to any multi-agent adaptive system with rare coordinated defectors (antimicrobial resistance, immune evasion modeling) — cross-domain reusability increases commercial surface area beyond oncology alone.

TIME_TO_RESULT_DAYS: 75

Implementation Sketch

# GPU ABM core (pseudocode, JAX/Taichi-style)
class SubcloneABM:
    agents: array[N, state]   # state: {type, position, fitness, resistance_level}
    signal_field: grid[X,Y]   # diffusible paracrine factor concentration

    def step(dt):
        signal_field = diffuse(signal_field, D) + secrete(agents)
        local_signal = sample(signal_field, agents.position)
        fitness = base_fitness(agents.type, drug_dose) + coop_bonus(local_signal)
        agents = reproduce_and_die(agents, fitness, dt)   # vectorized on GPU
        agents = mutate(agents, mutation_rate)
        return agents, signal_field

# Nash equilibrium comparator
def compute_nash(payoff_matrix):
    return replicator_dynamics_fixed_point(payoff_matrix)  # or best-response iteration

# Coalition-fit analysis
def fit_coalition_model(abm_trajectories):
    shapley_values = compute_shapley(abm_trajectories, characteristic_function)
    core_stability = test_core(abm_trajectories)
    r2 = compare_variance_explained(abm_trajectories, shapley_values, null_model)
    return r2, shapley_values

# Main sweep
for dose, diffusion_range, coop_strength, init_frac in parameter_grid(200):
    for seed in range(30):
        traj = run_abm(dose, diffusion_range, coop_strength, init_frac, seed, steps=10000)
        nash_pred = compute_nash(payoff_from_params(dose, coop_strength))
        deviation[dose, diffusion_range, coop_strength, init_frac, seed] = effect_size(traj[-1], nash_pred)
fit_coalition_model(all_trajectories)
run_ablations(['zero_range','shuffled_signal','scale_10x','scale_100x'])
Abort checkpoints:
  • Day 15 (after ABM sanity checks): if the ABM does not reproduce basic known qualitative resistance dynamics (e.g., dose-dependent selection for resistance) — abort and revise implementation before full sweep.
  • Day 35 (after initial 20% parameter sweep): if <10% of regimes show any deviation trend (d≥0.1), do a pre-registered interim analysis; if trend absent, halt full sweep to save GPU budget.
  • Day 55 (after ablations on subsample): if signal-shuffle ablation does not reduce deviation at all, abort further scale-up runs — mechanism is not coalition-based.

NAMED_EXPERTS: []

CLOSEST_EXISTING_WORK: []

NOVELTY_NARROWING_REQUIRED: true

Source

AegisMind Research
Need AI to work rigorously on your problems? AegisMind uses the same multi-model engine for personal and professional use. Get started